(ATX) is a multifunctional phosphodiesterase originally isolated from melanoma cells as a potent cell motilitystimulating factor. ATX is identical to lysophospholipase D that produces a bioactive phospholipid, lysophosphatidic acid (LPA), from lysophosphatidylcholine (LPC). Although enhanced expression of ATX in various tumor tissues has been repeatedly demonstrated, and thus ATX is implicated in progression of tumor, the precise role of ATX expressed by tumor cells was unclear. In this study we found that ATX is highly expressed in Glioblastoma multiforme (GBM), the most malignant glioma due to its high infiltration into the normal brain parenchyma, but not in tissues from other brain tumors. In addition, LPA 1 , an LPA receptor responsible for LPA-driven cell motility, is predominantly expressed in GBM. One of the glioblastoma that showed the highest ATX expression (SNB-78), as well as ATX-stable transfectants, showed LPA 1 -dependent cell migration in response to LPA in both Boyden-chamber and wound healing assays. Interestingly these ATX-expressing cells also showed chemotactic response to LPC. In addition, knockdown of the ATX level using siRNA technique in SNB-78 cells suppressed their migratory response to LPC. These results suggest that the autocrine production of LPA by cancer cell-derived ATX and exogenously supplied LPC contribute to the invasiveness of cancer cells and that LPA 1 , ATX and LPC-producing enzymes are potential targets for caner therapy, including GBM.
Introduction
Autotaxin (ATX) is a 125 kDa glycoprotein and a potent tumor cell motogen that was originally isolated from the conditioned medium of A2058 human melanoma cells as a cell-motility stimulating factor for melanoma cells (1) . ATX was subsequently identified as a member of a family of ecto/exoenzymes referred to as nucleotide pyrophosphatases/phosphodiesterases (NPPs) (2, 3) . The 3 cloned members of this family (PC-1/NPP1, ATX/NPP2, and B-10/NPP3) share a 47-55% amino acid sequence identity. PC-1/NPP1 and B-10/NPP3 hydrolyze 5'-phosphodiester bonds in nucleotides in vitro, while ATX/NPP2 shows only weak activity at hydrolyzing such bonds. ATX is synthesized as a type II membrane protein and is released from cells in a soluble form by an unknown mechanism (3, 4) . Enhanced expression of ATX in Ras-transformed NIH3T3 cells greatly enhances their invasive, tumorigenic and metastatic potentials (5) . In addition, enhanced expression of ATX has been repeatedly demonstrated in various malignant tumor tissues including non-small-cell lung cancer (6), breast 2 cancer (7, 8) , renal cell cancer (9) , hepatocellular carcinoma (10, 11) and thyroid cancer (12) , suggesting that ATX confers the tumorigenic and metastatic potentials of cancer cells. However, there is no direct evidence to show such a hypothesis so far. The mechanism by which ATX exhibits its biological activity toward various cancer cells was unknown. An ATX point mutant that is deficient in 5'-nucleotide phosphodiesterase activity was found to abolish the cell motility-stimulating activity of ATX (13) , indicating that the migratory response to ATX requires an intact catalytic site. Recently, we and others showed that ATX has lysophospholipase D (lysoPLD) activity which catalyzes a reaction to produce a bioactive lysophospholipid, lysophosphatidic acid (LPA), from lysophosphatidylcholine (LPC) (14, 15) . ATX has a significantly lower Km for LPC than the Km for the classical nucleotide substrate. Because LPA has long been defined as a cell motility-stimulating factor for various cell types including glioblastomas (16) (17) (18) , ATX has been suggested to regulate motility by producing LPA through the G protein-coupled receptor (GPCR). Indeed, recent studies have shown that ATX stimulates cell motility of various cancer cells in vitro through 1 of the LPA receptors, LPA 1 (19) (20) (21) (22) . Taking account of the fact that elevated ATX expression has been detected in various tumors (6) (7) (8) (9) (10) (11) (12) , it is possible that certain cancer cells utilize the ATX-LPC-LPA-LPA 1 system for their motility. In these cells, a possible regulatory factor that remains to be characterized is LPC. LPC is always present in plasma. In human plasma, its concentration ranges from 100 to 300 µM. LPC is also detected in other biological fluids such as seminal fluids and cerebrospinal fluids, and in tissues and various types of cells but at much lower concentrations than in plasma (23, 24) . Glioblastoma multiforme (GBM) is a highly malignant brain tumor. Removal of the tumor mass transiently improves the patient's condition, but the ability of GBM cells to infiltrate normal brain tissue invariably almost always leads to tumor recurrence. Thus, most patients experience recurrence within 1 year (25) and less than 20% of the patients survive more than 2 years (26) . GBM cells (glioblastomas) are highly motile and invade the normal brain parenchyma diffusely (27) . Several factors responsible for their invasive phenotype have been reported, such as, certain extracellular matrix proteins including laminin, fibronectin, and/or collagen can promote glioma cell migration (28, 29) . Secreted matrix metalloproteinases remodel the extracellular matrix creating pathways more conducive to migration through normal brain tissue (30) . Investigations of the factors that affect the motility of glioblastomas are of particular interest because an understanding of these factors is needed for valid GBM therapy. Because the blood brain barrier (BBB) is disrupted in GBM tissue, some components in plasma might affect cell motility of glioblastomas (31, 32) . In this study, we examined the expression of ATX and LPA 1 in brain tumor tissues and various tumor cell lines, and found that both ATX and LPA 1 are predominantly expressed in glioblastomas and GBM tissue. Using glioblastomas as a model system, we evaluated the effects of ATX, LPA 1 , LPA and LPC on the motility of the cells.
Materials and Methods

Reagents.
1-oleoyl-LPA (18:1) and 1-oleoyl-LPC (18:1) was purchased from Avanti Polar Lipids Inc. (Alabaster, AL). Ki16425 was kindly provided by Dr. Hideo Ohata (Kirin Brewery Co., Takasaki, Japan).
Cell lines.
All human tumor cell lines were maintained in RPMI 1640 (Sigma) supplemented with 2 mM glutamine, 1X penicillin/streptomycin and 5% (v/v) heatinactivated fetal bovine serum as described previously (33) . The cell lines used in this study were NCl-H23 (lung), NCl-H226 (lung), NCl-H522 (lung), NCl-H460 (lung), A549 (lung), DMS273 (lung), DMS114 (lung), HCC-2998 (colon), HT-29 (colon), WiDr (colon), HCT-15 (colon), DLD1 (colon), SW480 (colon), LOVO (colon), CaRI (rectum), WiDr (colon), CaCo2 (colon), Colo320 (colon), Colo201 (colon), HCT-116 (colon), KM12 3 (colon), HT1080 (colon), RXF-631L (renal), ACHN (renal), OVCAR3 (ovary), OVCAR4 (ovary), OVCAR5 (ovary), OVCAR8 (ovary), SKOV-3 (ovary), U251 (CNS), SF295 (CNS), SF539 (CNS), SF268 (CNS), SNB75 (CNS), SNB78 (CNS), MKN45 (stomach), MKN28 (stomach), St4 (stomach), MKN1 (stomach), MKN7 (Stomach), MKN74 (stomach), KatoIII (stomach), MKN28 (stomach), MKN45 (stomach), MKN74 (stomach), MDA-MB231 (breast), HBC4(breast), BSY1 (breast), MCF7 (breast), DU145 (prostate), PC3 (prostate), HPC5 (others), A2058 (melanoma) and HeLa (uterine cervix). Mouse 203G glioma cells were maintained in RPMI 1640 supplemented with 2 mM glutamine, 1X penicillin/streptomycin and 10% (v/v) heat-inactivated fetal bovine serum. This cell line was kindly provided by Dr. Koji Adachi (Nippon Medical School Tokyo, Japan).
Quantitative real-time RT-PCR.
From various cancer tissues and cancer cell lines total RNA from cells was isolated using ISOGEN (Nippongene, Toyama, Japan) and reversetranscribed using the SuperScript first-strand synthesis system for RT-PCR (Invitrogen). Oligonucleotide primers for PCR were designed using Primer Express Software (Applied Biosystems, Foster City, CA). 4 (mouse)-reverse GAGAGGGCCAGGTTGGTGAT; GAPDH (human/mouse)-forward GCCAAGGTCATCCATGACAACT; GAPDH (human/mouse)-reverse GAGGGGCCATCCACAGTCTT. PCR reactions were performed using an ABI Prism 7000 sequence detection system (Applied Biosystems). The transcript number of human GAPDH was quantified, and each sample was normalized on the basis of GAPDH content.
LysoPLD Assay.
Samples were incubated with 2 mM LPC (14:0) in the presence of 100 mM Tris-HCl (pH 9.0), 500 mM NaCl, 5 mM MgCl 2 , and 0.05% Triton X-100 during indicated hours at 37°C. The liberated choline was detected by an enzymatic photometric method as described (14) . Briefly, the liberated choline was oxidized by choline oxidase and the hydrogen peroxide generated was quantified using horseradish peroxidase and TOOS reagent (N-ethyl-N-(2-4 hydroxy-3-sulfoproryl)-3-methylanikine, Dojin, Tokyo, Japan).
SDS-PAGE/Western blotting.
Both cells and cell media were used to test for ATX protein expression. Cells were homogenized in PBS and then the cell homogenates separated into membrane and soluble fractions by centrifugation at 100,000 g for 60 min. Protein samples were separated by SDS-PAGE and transferred to nitrocellulose membranes using the Bio-Rad protein transfer system. The membranes were blocked with 10 mM Tris-HCl (pH7.5) containing 150 mM sodium chloride, 5% (w/v) skimmed milk and 0.05% (v/v) Tween 20, incubated with anti-lysoPLD monoclonal antibody (3D1) (23) , and then treated with anti-rat IgG-horseradish peroxidase. Proteins bound to the antibody were visualized with an enhanced chemiluminescence kit (ECL, Amersham Biosciences).
Isolation of stable ATX transfectant
The plasmid vector pCAGGS (kindly provided by Dr. Junichi Miyazaki (34)) was utilized to create rat ATX (ATX-t) tagged with the myc epitope at the C terminus (pCAGGS-rATXmyc). To establish stable transfectants, 203G glioma cells were transfected with pCAGGS-rATXmyc using Lipofectamine Plus reagents (Invitrogen) as recommended by the manufacturer and were grown in RPMI1640 containing 800 µg/ml G418 (Wako). Individual G418-resistant clones were isolated by limiting dilution and screened by immunocytochemistry using myc antibody, and by measuring the lysoPLD activities of the culture media.
Recombinant ATX preparations
Rat ATX was expressed and partially purified using baculovirus system as described previously (14) . The purified ATX was dialyzed in PBS and used for cell motility assays.
Boyden-chamber Assay
Chemotaxis was assayed as described previously (21) . In brief, polycarbonate filters with 8-µm pores (NeuroProbe, Inc., Gaithersburg, MD) were coated with 0.001% of fibronectin (Sigma). Cells (1 x 10 5 cells in 200 µl/well) were loaded into the upper chambers and incubated at 37°C for 6 h to allow migration. Cell migration to the bottom of the filter was evaluated by measuring optical density at 590 nm. For Ki16425 treatment, cells were preincubated with 1 µM Ki16425 for 30 min.
Wound healing assay
Cells were plated in cell culture plates (12-well) using cell growth media containing fetal bovine serum (FBS). After the cells had reached semiconfluence, FBS was removed from the media and replaced with serum-free media. A plastic pipette tip was drawn across the center of the plate to produce a clean wound area 24 h after serum depletion. Medium was then replaced with serum-free medium containing different concentrations of 1-oleoyl-LPA, 1-oleoyl-LPC, Ki16425 (1 µM) and lysoPLD. After the cells were cultured for 12 hr, 24 hr or 36 hr, cell movement into the wound area was examined. The migration distances between the leading edge of the migrating cells and the edge of the wound were compared.
Quantification of LPC
LPC concentration in cell culture supernatant was determined as described previously (35) . Briefly, cells were cultured in serum-free RPMI1640 containing 0.1% fatty acid-free bovine serum albumin (BSA, Sigma) for 2 days. LPC was extracted from culture media using the Bligh & Dyer method and re-suspended in phosphate buffered saline containing 0.1% BSA. LPC concentration was determined by a recently developed enzymatic coloriometric method as described. Briefly, samples were treated with lysophospholipase, glycerophosphorylcholine phosphodiesterase and choline oxidase. The resulting hydrogen peroxide generated was quantified using horseradish peroxidase and TOOS reagent.
RNA Interference
SNB-78 gliblastoma cells were transfected with siRNA oligo duplexes one day post confluence (day -1) with trans-it TKO (Takara, Kyoto, Japan) according to the manufacture's instruction. Generally 20 nM siRNA was transfected with 0.5 µl lipofectamine per well of a twenty-four well plate with fresh media. Each experiment contained equivalent samples transfected with a non-targeting control siRNA pool and samples not treated with trans-it TKO. siRNA oligonucleotide duplexes for each gene of interest were purchased from WAKO (Osaka, Japan) as optimized single duplexes ((ATX1,Sense:gccguuggagucaauaucuGC, Antisense:agauauugacuccaacggcAA) and (ATX2, Sense:gggagacugcuguaccaauTA, Antisense: auugguacagcagucucccCT)). Transfection efficiency was monitored using fluorescent (Cy3)-tagged oligonucleotides (Blockit, Invitrogen) transfected as described above and visualized with a mercury lamp fluorescent microscope.
Results
Expression of ATX and LPA receptors in 50 tumor cell lines
We examined the expression of ATX in 50 cultured human tumor cell lines derived from various tumors using the qRT-PCR technique. We found that some cells expressed a significant amount of ATX at both the mRNA and the protein levels ( Figs. 1 and 2 ). High ATX expression was detected in DMS273 (lung cancer), colo320 (colon cancer), SKOV3 (ovarian cancer), MKN1 (stomach cancer) and most of the brain cancer cells (SF295, SF539, SF268, SNB-75 and SNB-78). The expression was highest in SNB-78 cells. In good agreement with this observation, both ATX protein and lysophospholipase D activity was detected in the culture supernatants of these ATX-positive cells (Fig.  2) . Most of the protein was detected in the culture cell supernatants, while a small amount was detected in cells ( Fig. 2A) . These results confirm that ATX is secreted from cells, although ATX is initially biosynthesized in cells as a type II membrane protein.
We also examined the expression of the LPA receptors (LPA 1 , LPA 2 , LPA 3 and LPA 4 ) in the 50 human tumor cell lines using qRT-PCR. Although the expression pattern of the 4 LPA receptors does not necessarily reflect the tissue origin of the tumor cells, restricted LPA receptor expression patterns were obtained (Fig. 1) . LPA 2 was predominantly expressed in cells from colon, stomach and breast cancers (36, 37) . LPA 3 expression was relatively low. However, LPA 3 was expressed by certain ovarian and prostate cancer cell lines. Expression of LPA 4 was fairly low. By contrast, LPA 1 was dominant in brain tumor cells (Fig. 2) .
Expression of ATX and LPA receptors in GBM Because SF295, SF539, SF268, SNB-75 and SNB-78 are defined as glioblastomas (gliomas derived from glioblastoma multiforme (GBM)), we attempted to examine the expression of ATX and LPA receptors in tissues from various brain tumors. We found that expression of ATX was markedly high in GBM tissues (Fig. 3) . Three of 4 GBM tissue samples showed extremely high ATX expression. ATX expression is apparently lower in tissues from other brain tumors. One exception is a patient of astrocytoma (case AS2 No. 3) whose tissue showed high ATX expression. He experienced early recurrence after only 16 months and the tumor progressed to GBM at recurrence (case GBM No. 1). Among the four LPA receptors, LPA 1 was dominantly expressed in most brain tumor tissues tested including GBM with low expression of LPA 2 , LPA 3 and LPA 4 , which may reflect the expression pattern in normal brain tissues (38, 39) . The expression pattern of ATX and LPA receptors in GBM tissues indicates that ATX contributes to the invasive property of glioblastomas by producing LPA.
LPC stimulates cell motility of ATX-expressing cells
To test the possibility that glioblastomas acquire their high invasiveness through autocrine production of LPA by ATX, we first examined the effect of enhanced ATX expression on cell motility. We used 6 mouse glioma cell line 203G that expressed LPA 1 (Fig. 4A) but not a detectable amount of ATX (Fig.  4B) . 203G glioma cells that stably express ATX (203G-ATX) were established by transfecting ATX cDNA and by selecting neomycin-resistant clones. The established 3 lines expressed significant levels of ATX as judged by both lysoPLD activity (data not shown) and Western blotting (Fig. 4B) . In addition these cell lines showed similar expression pattern of LPA receptors to the parental 203G cells (data not shown). The effects of LPA on the motility of transfected cells and mock transfected 203G cells in the Boyden chamber were similar (Fig. 4C) . LPA had a similar effect on the motility of parental 203G cells (not shown). The effect of LPA on the motility of these cells was abolished by the LPA 1 antagonist, Ki16425 (Fig. 4C) . By contrast, these cells showed quite distinct responses to LPC. LPC significantly stimulated the migration of 203G-ATX cells in Boyden-chamber assay (Fig. 4D) . However, a similar response was not induced in mock transfected 203G cells (Fig. 4 D) or in parental 203G cells (not shown). In addition, the stimulatory effect of LPC in 203G-ATX cells was completely abolished by addition of Ki16425 (Fig. 4D) , showing that LPA mediates the LPC-stimulated cell migration of the cells through LPA 1 . We confirmed that platelet-derived growth factor induced similar migratory response both ATX-overexpressing, mock transfected and parental 203G cells (data not shown). We further examined the role of endogenously expressed ATX in the cell motility of ATXexpressing cells, which has not been previously demonstrated so far. For this experiment, we used SNB-78, which has the highest ATX expression among the 50 tumor cell lines (Fig. 1) . As shown in Fig. 5A , SNB-78 cells, like other LPA 1 -positive cells, showed a migratory response to exogenous LPA in the Boyden-chamber. LPC also stimulated the migration of SNB-78 (Fig. 5B) . Ki16425 blocked not only the LPA-induced migratory response but also the LPC-induced migratory response (Fig. 5) . This indicates that (1) LPC is converted to LPA by the lysoPLD activity of endogenous ATX, (2) the LPA generated subsequently stimulates cell migration through LPA 1 , and (3) LPC behaves as a chemotactic factor toward ATX-expressing cells. We previously showed that LPC is released from cells and could be converted to LPA to induce cell migration by exogenously added ATX (14) . In fact, SNB-78 was found to release a small amount of LPC into the cell culture medium, and the amount gradually increased during the culture (data not shown). However, we were unable to evaluate the effect of cell-derived LPC on cell motility in the Boyden-chamber since LPC is lost during preparation of the cells for the Boyden chamber assay. Accordingly, to evaluate the effects of cellderived LPC and ATX on cell migration, we used a wound healing assay, which takes a relatively long period. As expected, exogenously added LPA was able to induce migration of SNB-78 cells in the wound healing assay (Fig. 6A) . The migratory response was abolished by Ki16425, which shows that LPA 1 is involved in this system, as was observed in Boyden-chamber assay (Fig. 6A) . In the absence of exogenous LPC, we observed a weak migratory response, which was also blocked by Ki16425 (Fig. 6B) , showing that endogenous LPC and ATX, to a lesser extent, contribute to the migration of SNB-78 cells. By contrast, strong migratory responses were observed when LPC (10 µM) was added to the cells. The migratory response induced by LPC was again inhibited by Ki16425 (Fig. 6C) . The amount of LPC released from SNB-78 was ~50 nM as judged by the enzymatic coloriometric method for determination of LPC. This indicates that the amount of endogenous LPC released from SNB-78 is insufficient to induce a full migratory response in the cells and that exogenous LPC is potentially a key factor in controlling the migratory response of ATX-expressing cells.
ATX is responsible for motility of SNB-78 cells in wound healing assay
Our data suggests that endogenously expressed ATX in SNB-78 cells plays a key role in the motility of the cells by producing LPA from endogenously or exogenously supplied LPC. To confirm this hypothesis we used siRNA to down-regulate the 7 expression of ATX in SNB-78 cells. Confluent SNB-78 cells were transfected with varying amounts of siRNA duplexes using scramble siRNA as a control. As shown in Fig. 7 , after 48 hours of culture successful downregulation of ATX in the cell culture supernatants was confirmed by measuring lysoPLD activity of the cukture cell supernatant. We next performed the wound healing assay using the ATX-downregulated cells. We found that motility of SNB-78 cells was significantly suppressed both in the absence or presence of LPC, when the cells were treated with siRNA to suppress ATX expression (Fig.  8) . Exogenously added LPA was able to induce migration of ATX-downregulated cells (Fig. 8) , showing the siRNA-treated cells still retained the migratory activity in response to LPA. Thus, we concluded that ATX contributes to the cell migration of SNB-78 cells in the wound healing assay.
Discussion
Glioblastoma multiforme (GBM) is the most malignant brain tumor due to its high invasiveness. In this study we found that ATX, a cell motilitystimulating factor (4) is overexpressed in GBM tissues and many glioblastoma cell lines. ATX has catalytic activity to produce a potent chemoattractant-like lipid, LPA, and stimulates cell motility through an LPA G-protein coupled receptor, LPA 1 (14, 21) . Interestingly, both GBM tissues and glioblastomas express high levels of LPA 1, and in fact the glioblastoma, SNB-78, used in this study showed migratory responses not only to LPA but also to LPC (Figs. 5 and 6 ). In addition, suppression of ATX expression in SNB-78 cells by siRNA resulted in dramatical reduction of migratory response of the cells to LPC but not to LPA (Fig. 8) . Furthermore, LPA 1 antagonist, Ki16425, effectively suppressed both LPA-and LPC-induced motility of glioblastoma cells. Thus, the motility of glioblastoma cells appears to depend on ATX and LPA 1. LPA-induced cell motility of glioblastomas was also shown in the previous report by Manning et al. (16) .
Enhanced ATX expression has been repeatedly demonstrated in various tumors, including nonsmall-cell lung cancer, breast cancer, renal cell cancer, hepatocellular carcinoma and thyroid cancer (6) (7) (8) (9) (10) (11) (12) . In breast cancer, ATX expression level strongly correlates with the invasiveness of cancer cells (8) . Thus, it is reasonable to assume that ATX expressed by tumor cells is responsible for the motility and thus invasiveness of the cells. However, the spontaneous motility of non-small-cell lung cancer cells in vitro did not correlate with the levels of ATX mRNA (6) , indicating that other factors may influence ATX-induced cell motility. In this study we used glioblastoma cell lines that endogenously express ATX and cell transformants overexpressing ATX and evaluated ATX, LPA 1 and LPC, a substrate for ATX of lysoPLD activity. Our results show that LPC is a critical factor that regulates ATX-mediated cell motility. We previously showed that LPC is synthesized and released from various tumor cells, and that it is a potential substrate for ATX when ATX is added to the cells in the absence of exogenous LPC (14) . However, the concentration of cell derived LPC (~ 50 nM) is too low to induce full cell motility of SNB-78 cells (Fig. 6) . Although a high dose of exogenously added ATX induced cell motility (by converting cell derived LPC to LPA), the amounts of endogenously expressed ATX in glioblastoma cells and even in ATX-overexpressing gliomas cells were insufficient to have an affect on cell motility. We found that addition of exogenous LPC to the ATX-expressing cells but not ATXnegative cells strongly induced cell motility, although LPA equally promoted the motility of both cell types (Figs. 4-6) . Thus, LPC is a chemotactic factor for tumor cells expressing ATX and LPA 1 . LPC has previously been shown to act as a chemotactic factor for other cell types, including macrophages (40), monocytes (41), and Tlymphocytes (42) . In some cell types, such as macrophages, cell motility appears to be induced by another system (LPC-specific G-protein coupled receptor, G2A) (43) , while in other cell types, cell motility appears to be induced by the ATX-LPA 1 system.
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In general, the blood brain barrier (BBB) is disrupted in GBM tissue, which leads to exposure of tumor cells to components of plasma that might affect the cell motility of glioblastomas (31, 32) . As indicated by Manning et al., one such plasma component may be LPA (16) . However, LPA concentration in plasma is quite low (below 50 nM) although in serum it may be above 1 µM (44, 45) . In contrast, LPC concentration in plasma is extremely high (100-300 µM in human and ~500 µM in rats) (35, 44) . The concentration of LPC in brain tissue, such as in cerebrospinal fluids, is quite low (several µM level) (46) . Thus, when the BBB is disrupted in GBM, it is likely that these tumors are exposed to LPC derived from plasma. LPC is converted to LPA by ATX expressed by glioblastomas and consequently LPA 1 is activated, leading to the enhanced cell motility and high invasiveness of GBM (Fig. 9) . This idea is supported by the finding that GBM cells travel along blood vessels (47) . The expression patterns of LPA receptors in the 50 cancer cell lines (Fig. 1) agree with the previous reports on LPA receptor expression. For example, LPA 3 expression is relatively high in cells from ovarian cancer (48) and, markedly, LPA 2 is predominantly expressed in cells derived from colon (37) and thyroid cancer (49) . Recently, we also observed similar LPA receptor distribution patterns in human breast cancers (36) where LPA 2 expression is dramatically enhanced. The present study revealed that LPA 1 is predominantly expressed in GBM cells and tissues. The same is true for ATX. Thus, the expression patterns in cancer cell lines are definitely informative to understand the roles of ATX and LPA receptors in cancer cell biology. ATX may contribute to cancer cell survival and motility in several ways. In addition to its cell motility-stimulating activity, ATX has a cell proliferation-stimulating activity (14) and an angiogenic factor-like activity that induces new vessel formation by an unknown mechanism (50) . GBM is known to induce vascular proliferation and so ATX might have a role here as well. In summary, our results show that ATX, a potent oncogenic protein, is overexpressed in GBM and stimulates the motility of glioblastomas. Thus, ATX is a potential diagnostic marker for GBM. In addition, ATX, LPA 1 and unidentified LPC-producing enzymes are potential targets for GBM therapy. 
